Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akorn, Inc. stock logo
AKRX
Akorn
$0.19
$0.09
$5.46
$3.60M0.959.60 million shs1.19 million shs
Akorn, Inc. stock logo
AKRXQ
Akorn
$0.03
$0.03
$0.01
$5.40
$3.60MN/A7.44 million shsN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
$3.91
+2.9%
$4.54
$3.80
$8.05
$531.37M0.1523,521 shs8,567 shs
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
$0.02
$0.02
$0.01
$0.10
$1.13M1.613,441 shs4,032 shs
Teligent, Inc. stock logo
TLGT
Teligent
$0.03
$0.17
$1.60
N/AN/AN/A6,460 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akorn, Inc. stock logo
AKRX
Akorn
0.00%0.00%0.00%0.00%0.00%
Akorn, Inc. stock logo
AKRXQ
Akorn
0.00%0.00%0.00%0.00%0.00%
InnovAge Holding Corp. stock logo
INNV
InnovAge
-4.76%-5.00%-10.38%-35.15%+379,999,900.00%
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
-3.11%+0.75%-0.49%+1.25%-42.63%
Teligent, Inc. stock logo
TLGT
Teligent
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/AN/AN/AN/A
Akorn, Inc. stock logo
AKRXQ
Akorn
N/AN/AN/AN/AN/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.8441 of 5 stars
3.02.00.00.01.70.00.6
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/A
Akorn, Inc. stock logo
AKRXQ
Akorn
N/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
2.00
Hold$6.5066.24% Upside
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/A

Current Analyst Ratings

Latest AKRX, AKRXQ, TLGT, NXEN, and INNV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/13/2024
InnovAge Holding Corp. stock logo
INNV
InnovAge
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$7.00 ➝ $6.00
2/8/2024
InnovAge Holding Corp. stock logo
INNV
InnovAge
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akorn, Inc. stock logo
AKRX
Akorn
$682.43M0.00N/A0.19$1.86 per share0.00
Akorn, Inc. stock logo
AKRXQ
Akorn
$682.43M0.01N/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
$688.09M0.77N/AN/A$2.23 per share1.75
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/AN/AN/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akorn, Inc. stock logo
AKRX
Akorn
-$226.77M-$0.34N/AN/AN/A-55.64%8.53%1.31%N/A
Akorn, Inc. stock logo
AKRXQ
Akorn
-$226.77MN/A0.00N/AN/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$40.67M-$0.25N/A391.00N/A-4.38%-10.53%-5.69%5/7/2024 (Confirmed)
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
-$360K-$0.01N/AN/AN/AN/A-869.86%5/17/2024 (Estimated)
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest AKRX, AKRXQ, TLGT, NXEN, and INNV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$0.04N/A+$0.04N/AN/AN/A  
2/5/2024Q2 2024
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$0.03-$0.03N/A-$0.03$181.51 million$188.90 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/A
Akorn, Inc. stock logo
AKRXQ
Akorn
N/AN/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
N/AN/AN/AN/AN/A
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/AN/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akorn, Inc. stock logo
AKRX
Akorn
0.09
0.50
0.32
Akorn, Inc. stock logo
AKRXQ
Akorn
N/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.26
1.27
1.27
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/A
0.01
0.01
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akorn, Inc. stock logo
AKRX
Akorn
64.03%
Akorn, Inc. stock logo
AKRXQ
Akorn
N/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
12.26%
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
N/A
Teligent, Inc. stock logo
TLGT
Teligent
N/A

Insider Ownership

CompanyInsider Ownership
Akorn, Inc. stock logo
AKRX
Akorn
3.90%
Akorn, Inc. stock logo
AKRXQ
Akorn
3.90%
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.41%
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
30.60%
Teligent, Inc. stock logo
TLGT
Teligent
0.17%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akorn, Inc. stock logo
AKRX
Akorn
2,227133.15 millionN/AOptionable
Akorn, Inc. stock logo
AKRXQ
Akorn
2,227133.45 million128.25 millionNot Optionable
InnovAge Holding Corp. stock logo
INNV
InnovAge
2,100135.90 million135.34 millionOptionable
Nexien BioPharma, Inc. stock logo
NXEN
Nexien BioPharma
467.47 million46.83 millionNot Optionable
Teligent, Inc. stock logo
TLGT
Teligent
2,357N/AN/AOptionable

AKRX, AKRXQ, TLGT, NXEN, and INNV Headlines

SourceHeadline
Topical pain reliever recalled for problem that can cause ‘severe morbidity, even death’Topical pain reliever recalled for problem that can cause ‘severe morbidity, even death’
charlotteobserver.com - June 7 at 10:18 AM
β1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzzβ1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzz
news.google.com - May 13 at 1:32 AM
Lidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan NewsLidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan News
news.google.com - May 13 at 1:32 AM
Global Mobile Value-Added Services (VAS) Industry Market Report ... - Industry TodayGlobal Mobile Value-Added Services (VAS) Industry Market Report ... - Industry Today
news.google.com - May 11 at 4:41 AM
Global Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern ExaminerGlobal Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern Examiner
news.google.com - May 8 at 10:54 AM
Dry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPRDry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPR
news.google.com - May 8 at 5:54 AM
Mobile Value-Added Services (VAS) Market Size, Growth ... - Digital JournalMobile Value-Added Services (VAS) Market Size, Growth ... - Digital Journal
news.google.com - May 8 at 5:54 AM
Mobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern ExaminerMobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern Examiner
news.google.com - May 5 at 9:12 AM
Epinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital JournalEpinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital Journal
news.google.com - May 3 at 7:08 AM
Erythromycin Market with Focus on Growth Analysis, Production ... - Digital JournalErythromycin Market with Focus on Growth Analysis, Production ... - Digital Journal
news.google.com - May 2 at 8:42 AM
From 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital JournalFrom 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital Journal
news.google.com - April 29 at 8:17 AM
Tremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPRTremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPR
news.google.com - April 28 at 10:17 PM
Drugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPRDrugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPR
news.google.com - April 26 at 1:32 PM
Topical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPRTopical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPR
news.google.com - April 26 at 8:32 AM
Triamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan NewsTriamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan News
news.google.com - April 24 at 4:23 PM
IDT Corp. Cl BIDT Corp. Cl B
wsj.com - April 23 at 2:59 AM
Mobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital JournalMobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital Journal
news.google.com - April 17 at 2:17 PM
Hikma Names Injectables Chief Mishlawi As CEO - Generics BulletinHikma Names Injectables Chief Mishlawi As CEO - Generics Bulletin
news.google.com - April 12 at 1:13 PM
Mobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital JournalMobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital Journal
news.google.com - April 10 at 1:16 PM
Everstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin GlobeEverstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin Globe
news.google.com - April 6 at 1:58 PM
Lidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital JournalLidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital Journal
news.google.com - March 29 at 7:08 AM
Mobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital JournalMobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital Journal
news.google.com - March 29 at 2:07 AM
Gonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPRGonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPR
news.google.com - March 28 at 10:26 AM
Bankruptcy Standing: An Introduction to a Multitude | Reed Smith ... - JD SupraBankruptcy Standing: An Introduction to a Multitude | Reed Smith ... - JD Supra
news.google.com - March 25 at 8:59 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akorn logo

Akorn

NASDAQ:AKRX
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Akorn logo

Akorn

OTCMKTS:AKRXQ
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
InnovAge logo

InnovAge

NASDAQ:INNV
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.
Nexien BioPharma logo

Nexien BioPharma

OTCMKTS:NXEN
Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
Teligent logo

Teligent

NASDAQ:TLGT
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.